Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Alnylam (Group)

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. ONPATTRO, available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi therapeutic. Alnylam has a deep pipeline of investigational medicines, including three product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people worldwide and is headquartered in Cambridge, MA. *

 

Period Start 2002-01-01 established
Products Industry RNAi technology
  Industry 2 RNAi drug (RNAi therapeutic)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 300 Third Street
  City 02142 Cambridge, MA
  Tel +1-617-551-8200
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2018-08-29)
  Currency USD
  Annual sales 50,900,000 (revenue, consolidated (2007) 2007-12-31)
  Profit -85,500,000 (2007-12-31)
  Cash 443,873,000 (2008-03-31)
     
    * Document for �About Section�: Alnylam Pharmaceuticals, Inc.. (8/29/18). "Press Release: Alnylam to Webcast Presentations at Upcoming September Investor Conferences". Cambridge, MA.
     
   
Record changed: 2020-02-19

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Alnylam (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top